Delving into the Latest Updates on Tuberculosis vaccine(Aeras Technologies LLC) with Synapse

Overview

Basic Info

Drug Type

Recombinant vector vaccine, Prophylactic vaccine

Synonyms

Tuberculosis vaccine

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Pulmonary TuberculosisTuberculosis

Inactive Indication-

Originator Organization

Aeras Technologies LLC

Active Organization

Crucell Holdings, Inc.

Saint Louis University

Aeras Global TB Vaccine Foundation

+ [3]

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This trial will investigate the administration of two new tuberculosis vaccines, called AERAS-402 and MVA85A. The purpose of this trial is to assess what happens when both of these vaccines are given one after the other. The trial will assess the safety of both vaccines and also their ability to stimulate an immune response within the body. It is hoped that when these two vaccines are given in sequence, the combined immune response is even better than when each vaccine is used individually.

Start Date01 Sep 2012

Sponsor / Collaborator

University of Oxford

[+4]

NCT01378312

/ CompletedPhase 1IIT

A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-402 When Administered to HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

This Phase I study will be conducted as a randomized, double-blind, placebo-controlled study in healthy adult subjects who are HIV-negative, BCG-vaccinated, and have no evidence of tuberculosis infection. The study will be conducted at one clinical research site in India.
The available live tuberculosis vaccine, Bacillus Calmette-Guérin (BCG), provides incomplete protection against pulmonary tuberculosis. For unknown reasons, a BCG revaccination or "booster", while not toxic, does not provide much additional protection. AERAS-402 presents tuberculosis antigens in the setting of a new, live, replication-deficient adenovirus vaccine that may increase T cell-mediated immunity and thus protection from tuberculosis. Since BCG-vaccinated individuals are the population for which AERAS-402 might be indicated, AERAS-402 will be administered to individuals already vaccinated with BCG.

Start Date01 Feb 2011

Sponsor / Collaborator

Aeras Global TB Vaccine Foundation

100 Clinical Results associated with Tuberculosis vaccine(Aeras Technologies LLC)

Login to view more data

100 Translational Medicine associated with Tuberculosis vaccine(Aeras Technologies LLC)

Login to view more data

100 Patents (Medical) associated with Tuberculosis vaccine(Aeras Technologies LLC)

Login to view more data

915

Literatures (Medical) associated with Tuberculosis vaccine(Aeras Technologies LLC)

10 Jan 2025·ACS Infectious Diseases

Testing the Antigenic Potential of Transmembrane Proteins To Develop a Thermostable Tuberculosis MOF-Liposomal Vaccine

Article

Author: Meloni, Gabriele ; Kumari, Sneha ; Miles, Joshua ; Izzo, Angelo ; Martinez-Garcia, Jonathan ; Lu, Lenette ; Howlett, Thomas Sinclair ; Wijesundara, Yalini Hansika ; Gassensmith, Jeremiah J. ; Basak, Priyanka ; Restrepo, Blanca ; Tang, Wendy ; Ehrman, Ryanne Nicole ; Wang, Ziqi

Tuberculosis is one of the deadliest infectious diseases and continues to be a major health risk in many parts of the world. Even today, the century-old Bacillus Calmette-Guerin (BCG) vaccine is the only formulation on the market and is ineffective for several sections of the global population responsible for transmission. In the search for antigens that can mount a robust immune response, we have reported the recombinant expression and purification of two novel membrane proteins, the Cation transporter protein V (CtpV) and the Mycobacterial copper transporter B (MctB) present on the membrane surface of Mycobacterium tuberculosis. CtpV was tested as an antigen against the plasma of tuberculosis patients and was found to have a unique immune response profile compared with more commonly studied tuberculosis (TB) antigens. CtpV and MctB were reconstituted into proteoliposomes─individually and in combination─to stabilize them in a lipid bilayer and create a nanoparticle vaccine platform. In vivo experiments demonstrated that when delivered with an adjuvant, these antigens generated a robust Th1-biased T-cell response in mice, with the combination of both antigens performing the best and generating a response comparable to BCG. Since tuberculosis vaccines often need to be shipped to areas with fluctuating power supply, we encapsulated the proteoliposomes and the adjuvant in ZIF-8 to create a shelf-stable formulation. Complementary in vivo studies were carried out to confirm that the ZIF-8 coating did not interfere with or compromise the immunogenicity of the antigens.

01 Jan 2025·International Immunopharmacology

Cationic pH-sensitive liposomes as tuberculosis subunit vaccine delivery systems: Effect of liposome composition on cellular innate immune responses

Article

Author: Bouwstra, J A ; Geluk, A ; Szachniewicz, M M ; Jiskoot, W ; Kavrik, E ; Meijgaarden, K E van ; Haks, M C ; Ottenhoff, T H M

Tuberculosis (TB) is a major global health problem, and the development of effective and safe vaccines is urgently needed. CD8⁺ T-cells play an important role alongside CD4⁺ T-cells in the protective immune response against TB. pH-sensitive liposomes are hypothesized to boost CD8⁺ T-cell responses by promoting class I presentation through a mechanism involving pH-dependent endosomal escape and the cytosolic transfer of antigens. The aim of the study was to explore the potential of pH-sensitive liposomes as a novel delivery system for a multi-stage protein subunit vaccine against TB in primary human cells. The liposomes were formulated with the fusion antigen Ag85b-ESAT6-Rv2034 (AER), which was previously shown to be effective in reducing bacterial load in the lungs HLA-DR3 transgenic mice and guinea pigs. The liposomes were assessed in vitro for cellular uptake, cell viability, upregulation of cell surface activation markers, induction of cytokine production using human monocyte-derived dendritic cells (MDDCs), and activation of human antigen-specific T-cells. Liposome DOPC:DOPE:DOBAQ:EPC (3:5:2:4 M ratio) was effectively taken up, induced several cell surface activation markers, and production of CCl3, CCL4, and TNFα in MDDCs. It also induced upregulation of CD154 and IFNγ in T-cell clones in an antigen-specific manner. Thus, cationic pH-sensitive liposome-based TB vaccines have been demonstrated to be capable of inducing robust protective Mtb-specific immune responses, positioning them as promising candidates for effectiveTBvaccination.

31 Dec 2024·Journal of Leukocyte Biology

Specific BCG-related gene expression levels correlate with immune cell infiltration and prognosis in melanoma

Article

Author: Ren, He ; Han, Liang ; Hao, Jianlei ; Jiang, Guoqian ; Dong, Jie ; He, Jiacheng

AbstractMelanoma, caused by malignant melanocytes, is known for its invasiveness and poor prognosis. Therapies are often ineffective due to their heterogeneity and resistance. Bacillus Calmette-Guérin (BCG), primarily a tuberculosis vaccine, shows potential in treating melanoma by activating immune responses. In this study, data from The Cancer Genome Atlas and the National Center for Biotechnology Information Gene Expression Omnibus database were utilized to determine pivotal DEGs such as DSC2, CXCR1, BOK, and CSTB, which are significantly upregulated in BCG-treated blood samples and are strongly associated with the prognosis of melanoma. We employ tools like edgeR and ggplot2 for functional and pathway analysis and develop a prognostic model using LASSO Cox regression analysis to predict patient survival. A notable finding is the correlation between BCG-related genes and immune cell infiltration in melanoma, highlighting the potential of these genes as both biomarkers and therapeutic targets. Additionally, the study examines genetic alterations in these genes and their impact on the disease. This study highlights the necessity of further exploring BCG-related genes for insights into melanoma pathogenesis and treatment enhancement, suggesting that BCG's role in immune activation could offer novel therapeutic avenues in cancer treatment.

100 Deals associated with Tuberculosis vaccine(Aeras Technologies LLC)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tuberculosis	Phase 3	MZ	Aeras Global TB Vaccine Foundation	01 Sep 2010
Tuberculosis	Phase 3	KE	Aeras Global TB Vaccine Foundation	01 Sep 2010
Tuberculosis	Phase 3	ZA	Aeras Global TB Vaccine Foundation	01 Sep 2010
Pulmonary Tuberculosis	Phase 2	-	National Institutes of Health	-
Pulmonary Tuberculosis	Phase 2	-	Crucell Holdings, Inc.	-
Pulmonary Tuberculosis	Phase 2	-	Aeras Technologies LLC	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02414828 (Pubmed \| Pediatrics \| Am J Respir Crit Care Med) Manual	Phase 2	Tuberculosis	72	AERAS-402	(ykolcdfmfu) = aijtzfjlpz pdtcemxnun (ypjhjandoj )	Positive	01 May 2017
				Placebo	(ykolcdfmfu) = kjgoltdbld pdtcemxnun (ypjhjandoj )
NCT02414828 (C-010-402, CTgov)	Phase 2	Pulmonary Tuberculosis	72	Placebo (Placebo)	vytietbzoo(knzzvhwiet) = dpdgugybok hwnlnpnwid (hwmrcwqrov, dhdmhzbtlk - rezwlnmsby) View more	-	04 May 2016
				AERAS-402 3 x 10^8 vp (AERAS-402 3 x 10^8 vp)	vytietbzoo(knzzvhwiet) = ufrdmiecbp hwnlnpnwid (hwmrcwqrov, kmyxbishio - giyrjtishc) View more
NCT01198366 (CTgov)	Phase 1/2	Tuberculosis	487	placebo (Dose Finding - Group 1)	mbfanvrpjw(webxvlehil) = lyqdzfffji hgkmkmhfls (bincmwzwpd, mnjcxprtqt - hjogvawmla) View more	-	04 Aug 2015
				AERAS-402 (Dose Finding - Group 2)	mbfanvrpjw(webxvlehil) = pychtysrur hgkmkmhfls (bincmwzwpd, zpjphoxazr - gmaqknpnlx) View more
NCT01017536 (CTgov)	Phase 2	Tuberculosis \| HIV Infections	26	Placebo (Placebo)	(zqopojzpdz) = kekkzcmsbh lrjvrbfwwk (ysmealmyra, mqisgricir - mukbsftrsi) View more	-	13 Oct 2014
				AERAS-402 (Investigational Vaccine)	(zqopojzpdz) = bbzfobeahg lrjvrbfwwk (ysmealmyra, skjilyrqgw - hbkorfynus) View more